Cagrilintide / Tirzepatide Blend: dosing, reconstitution and evidence
A long-acting amylin analog paired with a dual GIP/GLP-1 agonist. The two suppress appetite through different mechanisms, which is the rationale for combining them.
Also known as CagriTirz, Cagri/Tirz, cagrilintide tirzepatide
Cagrilintide / Tirzepatide Blend quick start
- Route
- SubQ
- Typical dose
- 2.5–15 mg total blend per dose, titrated upward over months — confirm the split on your label
- Frequency
- Once weekly
- Half-life
- Both long-acting and suited to weekly dosing, which is why this pairing works as a blend where others do not.
- Cycle
- Ongoing while losing, with periodic reassessment.
- Vial sizes sold
- 20mg or 30mg
How to run it
- How often
- Once weekly
- Cycle length
- Ongoing while losing, with periodic reassessment.
- Half-life
- Both long-acting and suited to weekly dosing, which is why this pairing works as a blend where others do not.
- Route
- SubQ
What people actually run
The newest blend in wide circulation, following the trial data on combining an amylin analog with an incretin. Early adopters report the combination blunts appetite more than tirzepatide alone.
What to expect
Most people tolerate Cagrilintide / Tirzepatide Blend well. Here is what is worth knowing going in, so nothing catches you by surprise.
Known interactions
Interactions involving Cagrilintide / Tirzepatide Blend's drug class that DoseIQ screens for. Each one cites where it comes from — an FDA label section or the published record — because an interaction warning you can't trace is just noise.
Semaglutide, tirzepatide and retatrutide all cut appetite and glucose while the insulin dose was sized for the old intake — the mismatch is how hypos happen.
What to do: Prescribers usually reduce insulin when a GLP-1-class drug starts. Monitor glucose closely and have that conversation.
Source: FDA labels, semaglutide/tirzepatide §7
Sulfonylureas force insulin release regardless of glucose; adding any GLP-1-class drug on top is the classic hypoglycemia setup.
What to do: The sulfonylurea dose is usually reduced or stopped when a GLP-1-class drug starts — ask your prescriber if that conversation hasn't happened.
Source: FDA labels, semaglutide/tirzepatide §7
Tirzepatide slows gastric emptying enough to reduce oral contraceptive absorption — the label itself says so.
What to do: The label advises a barrier backup for 4 weeks after starting and after each dose increase.
Source: FDA label, tirzepatide §7.1
Growth hormone raises glucose and insulin resistance — it works directly against glucose-lowering medication.
What to do: Fasting glucose and HbA1c are worth tracking; medication doses sometimes need adjusting. Your prescriber should know GH peptides are in the picture.
Source: GH pharmacology; tesamorelin label §7
Even short prednisone courses raise glucose; diabetes control commonly loosens during a course.
What to do: Monitor glucose during the course; prescribers often adjust doses temporarily.
Source: FDA label, prednisone §7
The whole GLP-1 class — semaglutide, tirzepatide, retatrutide — delays gastric emptying, which changes how narrow-margin oral drugs (thyroid, warfarin, the pill) absorb.
What to do: Keep timing consistent, and re-check the relevant lab (TSH, INR) a few weeks after starting or increasing the dose.
Source: FDA labels, GLP-1 class §7
Levothyroxine dosing tracks body weight — significant weight loss on any GLP-1-class drug commonly means the old dose becomes too high.
What to do: Re-check TSH after meaningful weight change rather than waiting for symptoms.
Source: Levothyroxine dosing guidance (weight-based)
Both suppress appetite; together intake can drop genuinely too low without feeling like anything is wrong.
What to do: Track weight and actually eat protein on schedule — hunger stops being a reliable signal on this combination.
Source: Class pharmacology; widely reported in practice
The racing heart that warns of a low is exactly what a beta-blocker suppresses — lows sneak up quietly.
What to do: Anyone on this combination should know sweating remains a reliable warning sign when the heart rate isn't.
Source: FDA label, metoprolol §7
Lithium levels track hydration, and a rough titration week — nausea, vomiting, big drops in intake — concentrates lithium.
What to do: Drink deliberately during dose increases, and treat persistent vomiting as a reason to check a lithium level, not just wait out.
Source: Lithium label (volume depletion); GLP-1 class GI profile
Olanzapine and quetiapine drive weight and glucose up; GLP-1-class drugs are increasingly co-prescribed to counter exactly that.
What to do: Usually intentional — the job here is tracking: fasting glucose, HbA1c and lipids tell you whether the plan is working.
Source: Class pharmacology; current prescribing practice
Reconstitution guide
Cagrilintide / Tirzepatide Blend ships as a lyophilised powder and gets mixed with bacteriostatic water before use. How much water you add sets the concentration, which sets how many syringe units make up each dose. One unit on a U-100 syringe is 0.01 mL — the tables below do the arithmetic for the vial sizes you are most likely to be holding.
20mg vial most common
| Water added | Concentration | 2.5mg | 15mg |
|---|---|---|---|
| 1mL (common) | 20 mg/mL | 0.13 mL 12.5 units | 0.75 mL 75 units |
| 2mL | 10 mg/mL | 0.25 mL 25 units | 1.50 mL 150 units * |
30mg vial
| Water added | Concentration | 2.5mg | 15mg |
|---|---|---|---|
| 1mL (common) | 30 mg/mL | 0.08 mL 8.3 units | 0.50 mL 50 units |
| 2mL | 15 mg/mL | 0.17 mL 16.7 units | 1.00 mL 100 units |
* More than 100 units — that is more than a single U-100 insulin syringe holds. Either use a larger syringe, split it across two draws, or mix with less water to concentrate it. Adding less water is usually the easier fix.
Standard steps
- Inspect the vialConfirm the label and that the powder cake is intact. Do not use a cracked or compromised vial.
- Let it reach room temperatureSitting out for a few minutes reduces condensation inside the vial when the seal is broken.
- Disinfect both stoppersWipe the compound vial and the bacteriostatic water vial with a fresh alcohol swab and let them air-dry.
- Draw the bacteriostatic waterUse a sterile syringe to draw the volume you have chosen from the reconstitution table.
- Add the water down the vial wallInject slowly so it runs down the inside wall rather than spraying directly onto the powder. This limits foaming.
- Dissolve gentlySwirl or roll the vial between your hands until the cake dissolves. Never shake — agitation damages peptide bonds. The solution should end up clear.
- Label and refrigerateWrite the reconstitution date and concentration on the vial. Store at 2–8°C. Do not freeze.
This page is an educational research reference and is not medical advice. Cagrilintide / Tirzepatide Blend is not approved for human use in any jurisdiction. Dose figures reflect the published record and what the community has converged on — starting points to weigh, not instructions. Consult a qualified healthcare provider before starting any protocol.